Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial

Roche has shared the data that it hopes will secure approval for a subcutaneous formulation of its PD-L1 checkpoint inhibitor Tecentriq. Having revealed the top-line success in August, the Swiss drugmaker will use the ESMO Immuno-Oncology Congress 2022 to show off the figures behind the co-primary endpoint hits.